Helicobacter Pylori Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major helicobacter pylori markets reached a value of US$ 3,480.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3,891.7 Million by 2034, exhibiting a growth rate (CAGR) of 1.02% during 2024-2034.
The helicobacter pylori market has been comprehensively analyzed in IMARC's new report titled "Helicobacter Pylori Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Helicobacter pylori is a type of bacteria that infects the stomach lining, resulting in chronic inflammation and damage to the protective mucus layer. The ailment can spread through close contact with an infected person's saliva, vomit, or fecal matter. It can also be transmitted through the consumption of contaminated food or water. Some common symptoms of this disease include abdominal pain and discomfort, bloating, nausea, vomiting, lack of appetite, frequent burping, unexplained weight loss, heartburn or acid reflux, etc. In rare cases, individuals suffering from the illness might experience gastrointestinal bleeding, which can lead to the passage of black, tarry stools. The diagnosis of Helicobacter pylori can be made through a comprehensive evaluation of the patient's characteristic features, medical history, and physical examination. The healthcare professional may conduct various diagnostic investigations, including stool antigen analysis, urea breath test, blood antibody workup, etc., to detect the presence of bacteria and confirm the diagnosis. Furthermore, an endoscopy with tissue biopsy is recommended to assess the severity of inflammation or any other underlying conditions.
The increasing cases of bacterial diseases, which are transmissible through close personal contact, such as kissing or sharing utensils and food with an infected person, are primarily driving the Helicobacter pylori market. In addition to this, the rising prevalence of poor hygiene conditions that can contribute to the spread of the bacterium is also creating a positive outlook for the market. Moreover, the widespread adoption of combination therapy, which involves a proton pump inhibitor along with two antibiotics, usually clarithromycin and amoxicillin or metronidazole, to eradicate the pathogen and promote healing of the affected stomach lining, is further bolstering the market growth. Apart from this, the inflating application of polymerase chain reaction (PCR) technique, since it amplifies specific DNA sequences, thereby allowing rapid detection or quantification of even small amounts of the bacterial genome, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of injectable antibiotics on account of their several benefits over oral medications, such as optimal drug absorption and faster symptom relief, is expected to drive the Helicobacter pylori market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Helicobacter pylori market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Helicobacter pylori and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Helicobacter pylori market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Helicobacter pylori market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Helicobacter pylori market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Helicobacter pylori marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Helicobacter pylori market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Helicobacter pylori market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Helicobacter pylori market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Helicobacter pylori across the seven major markets?
What is the number of prevalent cases (2018-2034) of Helicobacter pylori by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Helicobacter pylori by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Helicobacter pylori across the seven major markets?
What is the size of the Helicobacter pylori patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Helicobacter pylori?
What will be the growth rate of patients across the seven major markets?
Helicobacter Pylori: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Helicobacter pylori drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Helicobacter pylori market?
What are the key regulatory events related to the Helicobacter pylori market?
What is the structure of clinical trial landscape by status related to the Helicobacter pylori market?
What is the structure of clinical trial landscape by phase related to the Helicobacter pylori market?
What is the structure of clinical trial landscape by route of administration related to the Helicobacter pylori market?
The helicobacter pylori market has been comprehensively analyzed in IMARC's new report titled "Helicobacter Pylori Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Helicobacter pylori is a type of bacteria that infects the stomach lining, resulting in chronic inflammation and damage to the protective mucus layer. The ailment can spread through close contact with an infected person's saliva, vomit, or fecal matter. It can also be transmitted through the consumption of contaminated food or water. Some common symptoms of this disease include abdominal pain and discomfort, bloating, nausea, vomiting, lack of appetite, frequent burping, unexplained weight loss, heartburn or acid reflux, etc. In rare cases, individuals suffering from the illness might experience gastrointestinal bleeding, which can lead to the passage of black, tarry stools. The diagnosis of Helicobacter pylori can be made through a comprehensive evaluation of the patient's characteristic features, medical history, and physical examination. The healthcare professional may conduct various diagnostic investigations, including stool antigen analysis, urea breath test, blood antibody workup, etc., to detect the presence of bacteria and confirm the diagnosis. Furthermore, an endoscopy with tissue biopsy is recommended to assess the severity of inflammation or any other underlying conditions.
The increasing cases of bacterial diseases, which are transmissible through close personal contact, such as kissing or sharing utensils and food with an infected person, are primarily driving the Helicobacter pylori market. In addition to this, the rising prevalence of poor hygiene conditions that can contribute to the spread of the bacterium is also creating a positive outlook for the market. Moreover, the widespread adoption of combination therapy, which involves a proton pump inhibitor along with two antibiotics, usually clarithromycin and amoxicillin or metronidazole, to eradicate the pathogen and promote healing of the affected stomach lining, is further bolstering the market growth. Apart from this, the inflating application of polymerase chain reaction (PCR) technique, since it amplifies specific DNA sequences, thereby allowing rapid detection or quantification of even small amounts of the bacterial genome, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of injectable antibiotics on account of their several benefits over oral medications, such as optimal drug absorption and faster symptom relief, is expected to drive the Helicobacter pylori market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Helicobacter pylori market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Helicobacter pylori and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Helicobacter pylori market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Helicobacter pylori market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Helicobacter pylori market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Helicobacter pylori marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Helicobacter pylori market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Helicobacter pylori market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Helicobacter pylori market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Helicobacter pylori across the seven major markets?
What is the number of prevalent cases (2018-2034) of Helicobacter pylori by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Helicobacter pylori by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Helicobacter pylori across the seven major markets?
What is the size of the Helicobacter pylori patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Helicobacter pylori?
What will be the growth rate of patients across the seven major markets?
Helicobacter Pylori: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Helicobacter pylori drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Helicobacter pylori market?
What are the key regulatory events related to the Helicobacter pylori market?
What is the structure of clinical trial landscape by status related to the Helicobacter pylori market?
What is the structure of clinical trial landscape by phase related to the Helicobacter pylori market?
What is the structure of clinical trial landscape by route of administration related to the Helicobacter pylori market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HELICOBACTER PYLORI - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HELICOBACTER PYLORI - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HELICOBACTER PYLORI - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HELICOBACTER PYLORI - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HELICOBACTER PYLORI - UNMET NEEDS
10 HELICOBACTER PYLORI - KEY ENDPOINTS OF TREATMENT
11 HELICOBACTER PYLORI - MARKETED PRODUCTS
11.1 List of Helicobacter Pylori Marketed Drugs Across the Top 7 Markets
11.1.1 Voquezna Triple Pak (vonoprazan/amoxicillin/clarithromycin) - Phathom Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Voquezna Dual Pak (vonoprazan/amoxicillin) - Phathom Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Talicia (Amoxicillin/omeprazole/rifabutin) - RedHill Biopharma
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Prilosec (Omeprazole) - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Nexium (Esomeprazole) - AstraZeneca
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HELICOBACTER PYLORI - PIPELINE DRUGS
12.1 List of Helicobacter Pylori Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. HELICOBACTER PYLORI - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HELICOBACTER PYLORI – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HELICOBACTER PYLORI - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Helicobacter Pylori - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Helicobacter Pylori - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Helicobacter Pylori - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Helicobacter Pylori - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Helicobacter Pylori - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Helicobacter Pylori - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Helicobacter Pylori - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Helicobacter Pylori - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Helicobacter Pylori - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Helicobacter Pylori - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Helicobacter Pylori - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Helicobacter Pylori - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Helicobacter Pylori - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Helicobacter Pylori - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Helicobacter Pylori - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Helicobacter Pylori - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Helicobacter Pylori - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Helicobacter Pylori - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Helicobacter Pylori - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Helicobacter Pylori - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Helicobacter Pylori - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Helicobacter Pylori - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Helicobacter Pylori - Access and Reimbursement Overview
16 HELICOBACTER PYLORI - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HELICOBACTER PYLORI MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HELICOBACTER PYLORI MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HELICOBACTER PYLORI - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HELICOBACTER PYLORI - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HELICOBACTER PYLORI - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HELICOBACTER PYLORI - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HELICOBACTER PYLORI - UNMET NEEDS
10 HELICOBACTER PYLORI - KEY ENDPOINTS OF TREATMENT
11 HELICOBACTER PYLORI - MARKETED PRODUCTS
11.1 List of Helicobacter Pylori Marketed Drugs Across the Top 7 Markets
11.1.1 Voquezna Triple Pak (vonoprazan/amoxicillin/clarithromycin) - Phathom Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Voquezna Dual Pak (vonoprazan/amoxicillin) - Phathom Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Talicia (Amoxicillin/omeprazole/rifabutin) - RedHill Biopharma
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Prilosec (Omeprazole) - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Nexium (Esomeprazole) - AstraZeneca
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HELICOBACTER PYLORI - PIPELINE DRUGS
12.1 List of Helicobacter Pylori Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. HELICOBACTER PYLORI - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HELICOBACTER PYLORI – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HELICOBACTER PYLORI - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Helicobacter Pylori - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Helicobacter Pylori - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Helicobacter Pylori - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Helicobacter Pylori - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Helicobacter Pylori - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Helicobacter Pylori - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Helicobacter Pylori - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Helicobacter Pylori - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Helicobacter Pylori - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Helicobacter Pylori - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Helicobacter Pylori - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Helicobacter Pylori - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Helicobacter Pylori - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Helicobacter Pylori - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Helicobacter Pylori - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Helicobacter Pylori - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Helicobacter Pylori - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Helicobacter Pylori - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Helicobacter Pylori - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Helicobacter Pylori - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Helicobacter Pylori - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Helicobacter Pylori - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Helicobacter Pylori - Access and Reimbursement Overview
16 HELICOBACTER PYLORI - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HELICOBACTER PYLORI MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HELICOBACTER PYLORI MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
